EGFR and non-small cell lung carcinoma: Specifically, in EGFR positive lung cancer patients treated with tyrosine kinase inhibitors (TKI) ctDNA has shown reliable correlations with tumor load and changes in response to treatment [3, 6–9], indicating a potential utility of this approach in the clinical management of NSCLC.